Aclaris Therapeutics, Inc.
ACRS
$2.83
-$0.05-1.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.87% | -47.56% | -42.87% | -40.09% | 27.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.87% | -47.56% | -42.87% | -40.09% | 26.35% |
| Cost of Revenue | -15.18% | -44.73% | -56.14% | -62.28% | -47.52% |
| Gross Profit | -10.15% | 43.02% | 62.01% | 70.64% | 66.25% |
| SG&A Expenses | -13.08% | -14.88% | -27.29% | -29.54% | -21.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.32% | -32.40% | -45.09% | -51.12% | -37.27% |
| Operating Income | -11.44% | 26.28% | 45.78% | 54.13% | 49.04% |
| Income Before Tax | -279.12% | -128.05% | -67.73% | -48.64% | 67.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -282.88% | -129.47% | -68.53% | -49.26% | 67.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -282.88% | -129.47% | -68.53% | -49.26% | 67.72% |
| EBIT | -11.44% | 26.28% | 45.78% | 54.13% | 49.04% |
| EBITDA | -12.00% | 26.10% | 45.70% | 54.17% | 37.24% |
| EPS Basic | -165.78% | -65.55% | -28.01% | -18.68% | 68.82% |
| Normalized Basic EPS | 33.67% | 55.54% | 62.57% | 63.20% | 55.09% |
| EPS Diluted | -164.73% | -65.20% | -27.82% | -18.54% | 68.67% |
| Normalized Diluted EPS | 33.67% | 55.54% | 62.57% | 63.20% | 55.09% |
| Average Basic Shares Outstanding | 62.64% | 44.93% | 27.17% | 10.70% | 3.50% |
| Average Diluted Shares Outstanding | 62.64% | 44.93% | 27.17% | 10.70% | 3.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |